Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma
- Cite this article as:
- Fossella, F.V., Winn, R.J., Holoye, P.Y. et al. Invest New Drugs (1992) 10: 331. doi:10.1007/BF00944191
- 29 Downloads
We treated 34 chemotherapy-naive patients with stage IIIb or IV non-small cell lung cancer with trimetrexate 150–200 mg/m2 intravenously over 30 minutes every two weeks. Six of 31 evaluable patients (19%) achieved a partial response. The major toxic effects from this regimen were myelosuppression, nausea/vomiting, and skin rash. We conclude that this well-tolerated schedule of trimetrexate has significant activity as a single agent against non-small cell lung cancer.